Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Azilsartan mepixetil - Wuhan Createrna Science and Technology

Drug Profile

Azilsartan mepixetil - Wuhan Createrna Science and Technology

Alternative Names: QR-01019

Latest Information Update: 10 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wuhan Createrna Science and Technology
  • Class Antihypertensives; Benzimidazoles; Biphenyl compounds; Esters; Ethers; Oxadiazoles; Pyrazines; Small molecules
  • Mechanism of Action Angiotensin type 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hypertension

Most Recent Events

  • 26 May 2023 US FDA approves clinical trial application for Azilsartan mepixetil in Essential hypertension (before May 2023)
  • 26 May 2023 Wuhan Createrna Science and Technology plans a clinical trial for Essential hypertension in the US
  • 17 Dec 2021 Phase-II clinical trials in Hypertension in China (PO), before December 2021 (Wuhan Createrna Science and Technology pipeline, December 2021).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top